Glaxo's asthma drug approved: The pharmaceutical giant has received a badly needed boost, reports Gail Counsell
Tuesday 09 March 1993
The drug, fluticasone propionate, is already available as a treatment for hay fever under the name Flixonase. But its extension to the pounds 2.5bn-a-year respiratory market is important for Glaxo, which badly needs to broaden its product base.
More than half of Glaxo's profits are currently dependent on one drug, Zantac, the anti-ulcer treatment, and the performance of some of its newer drugs has proved disappointing.
The news boosted Glaxo's share price, which went on a roller- coaster ride yesterday following weekend reports that America's Food and Drug Administration had criticised the marketing of Zantac. In heavy trading, its shares tumbled 28p but recovered to close down 8p at 652p.
Glaxo, under its chief executive, Ernest Mario, played down the reports, admitting that the FDA had written in January warning that in its view some of the promotional claims made for Zantac were not justified.
But Glaxo insisted that the 'safety and effectiveness' of Zantac had not been called into question, and pointed out that at most the FDA would require it to write to US physicians correcting certain of the claims it had made.
Analysts said the problem was commonly encountered by drug companies. 'It's a storm in a teacup,' Paul Woodhouse, an analyst with Smith New Court, said.
The Stock Exchange said that it would be looking as a matter of routine at the movement in the share price. The implication is that a statement should perhaps have been made by the company when the problem arose.
But Mr Woodhouse insisted that the issue had been well aired. 'This was raised and discussed with analysts following the interim results last month,' he said.
Flixotide is an improved version of an inhaled steroid, a type of drug increasingly used to treat asthma since it attacks the inflammation that causes the asthma. Conventional treatments such as Glaxo's best-selling Ventolin merely ease its symptoms. Flixotide will therefore be able to substitute for lost Ventolin sales. It is also held to be more powerful and to have fewer side-effects than other steroids on the market.
(Photograph and graph omitted)
Threat of 'catastrophic cascade of collisions' involving 300,000 pieces of rubbish must be averted, warn scientists
Oxford is the least affordable city in the UK, where houses cost 11 times local salaries
Swarm of killer bees sting woman 1,000 times
Malaysia Airlines Flight MH370: Oil slicks in South China Sea ‘not from missing jet’, officials say
Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
Oscar Pistorius trial: Athlete repeatedly throws up as court hears 'graphic details' of Reeva Steenkamp's autopsy
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
Poor 'live like animals' says Boris's privately educated sister after going on 'poverty safari'
Exclusive: Impact of immigrants on British workers ‘negligible’
Vince Cable: Teachers 'know absolutely nothing' about the world of work
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
The quiet diplomat: Catherine Ashton - recognised and admired in all the world’s troubled countries, yet ridiculed at home
- 1 Oxford is the least affordable city in the UK, where houses cost 11 times local salaries
- 2 Australian man Rod Sommerville reacts to bite from deadly snake by reaching for cold beer
- 3 North Korea elections: Kim Jong-un wins 100% of the vote
- 4 David Cameron resorts to paying for Facebook fans because not enough people like him
- 5 Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
iJobs Money & Business
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£55000 - £70000 per annum + benefits: Pro-Recruitment Group: In-House Corporat...
£80000 - £100000 per annum + benefits: Pro-Recruitment Group: In-House Opportu...
£30000 - £35000 per annum + generous benefits: Pro-Recruitment Group: Mixed Ta...